X
ESPR

Xponance’s Esperion Therapeutics ESPR Stock Holding History

Xponance’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.1K Buy
24,094
+3,120
+15% +$8.73K ﹤0.01% 1743
2026
Q1 		$57.5K Buy
20,974
+2,888
+16% +$9.14K ﹤0.01% 1626
2025
Q4 		$66.9K Buy
18,086
+2,498
+16% +$8.07K ﹤0.01% 1500
2025
Q3 		$41.3K Buy
15,588
+117
+0.8% +$226 ﹤0.01% 1497
2025
Q2 		$15.2K Buy
15,471
+1,530
+11% +$1.53K ﹤0.01% 1504
2025
Q1 		$20.1K Buy
13,941
+710
+5% +$1.31K ﹤0.01% 1424
2024
Q4 		$29.1K Buy
13,231
+1,145
+9% +$2.67K ﹤0.01% 1425
2024
Q3 		$19.9K Sell
12,086
-359
-3% -$725 ﹤0.01% 1379
2024
Q2 		$27.6K Buy
+12,445
New +$29.3K ﹤0.01% 1299

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Xponance's ESPR Position: Q2 2026 in Review

Xponance increased its Esperion Therapeutics (ESPR) stake by 15% in Q2 2026, buying an estimated $8.73K and bringing the position to 24,094 shares worth $76.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Xponance first reported a position in ESPR in Q2 2024 and has held it in 9 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Xponance held 24,094 shares of Esperion Therapeutics worth $76.1K as of Q2 2026.
  • Xponance bought 3,120 Esperion Therapeutics shares in Q2 2026, an estimated $8.73K.
  • Esperion Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1743 holding.
  • Xponance first reported a position in Esperion Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.